Core Viewpoint - Maravai LifeSciences Holdings, Inc. is facing a class action lawsuit due to allegations of false and misleading statements regarding its financial reporting and revenue recognition practices during the specified class period [3][4]. Group 1: Class Action Details - The class action lawsuit represents investors who purchased Maravai securities between August 7, 2024, and February 24, 2025 [1]. - Investors are encouraged to contact the Portnoy Law Firm for a complimentary case evaluation and to discuss their legal rights [2]. Group 2: Allegations Against Maravai - The lawsuit claims that Maravai lacked adequate internal controls over financial reporting, particularly concerning revenue recognition [3]. - It is alleged that Maravai improperly recognized approximately $3.9 million in revenue during fiscal year 2024 due to an error in recording revenue [4]. - The company is also accused of overstating its goodwill related to its acquisition of Alphazyme LLC [3][4]. Group 3: Impact on Stock Price - Following the announcement of the postponement of its fiscal 2024 earnings release and the need for additional time to complete its financial close, Maravai's stock price fell by nearly 22% [4].

NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI). Shareholders who purchased shares of MRVI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/maravai-lifesciences-holdings-inc-loss-submission-form/?id=14 ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Maravai Lifesciences Holdings, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on May 5, 2025 [1] Group 1: Class Action Details - Investors who purchased Maravai securities between August 7, 2024, and February 24, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [3][6] - The lawsuit claims that Maravai made false or misleading statements regarding its financial reporting and internal controls, leading to investor damages when the truth was revealed [5] Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4] - The firm has secured significant settlements for investors, including over $438 million in 2019 and has been consistently ranked among the top firms for securities class action settlements [4]

Group 1 - The outlook for Avantor (NYSE: AVTR) is described as uninspiring, despite some emerging positive indicators [1] - Avantor is facing challenges such as demanding earnings multiples, elevated debt levels, and underwhelming growth [1] - The company operates in the life sciences tools sector and serves as a partner to the industry [1] Group 2 - The investing group "Value In Corporate Events" focuses on identifying opportunities in major corporate events like IPOs, mergers & acquisitions, and earnings reports [1] - The group provides coverage of approximately 10 significant events each month to find the best investment opportunities [1]

Core Insights - Avantor, Inc. reported $1.58 billion in revenue for Q1 2025, a year-over-year decline of 5.9% [1] - The EPS for the same period was $0.23, slightly up from $0.22 a year ago, with no EPS surprise against the consensus estimate [1] - The reported revenue was a surprise of -1.72% compared to the Zacks Consensus Estimate of $1.61 billion [1] Revenue Breakdown - Bioscience Production revenue was $516.40 million, below the four-analyst average estimate of $530.71 million [4] - Laboratory Solutions revenue reached $1.07 billion, slightly below the $1.09 billion average estimate [4] Operating Income Analysis - Adjusted Operating Income for Laboratory Solutions was $139 million, exceeding the average estimate of $128.24 million [4] - Adjusted Operating Income for Corporate was -$19.60 million, worse than the average estimate of -$14.91 million [4] - Adjusted Operating Income for Bioscience Production was $123.40 million, slightly above the average estimate of $121.23 million [4] Stock Performance - Avantor's shares returned -4.1% over the past month, compared to the Zacks S&P 500 composite's -4.8% change [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance in the near term [3]

LEXINGTON, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release first quarter 2025 financial results prior to the market open on Friday, May 9, 2025. In conjunction with the release, the Company’s management team will host a webcast conference call at 8:30 a.m. ET ...

Company Overview - Azenta, Inc. (Nasdaq: AZTA) is a leading provider of life sciences solutions globally, facilitating faster market access for impactful breakthroughs and therapies [3] - The company offers a comprehensive range of reliable cold-chain sample management solutions and multiomics services, focusing on drug development, clinical research, and advanced cell therapies [3] - Azenta operates under several industry-leading brands, including GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, and Barkey [3] Financial Announcement - Azenta will announce its fiscal second quarter 2025 earnings on May 7, 2025, before the market opens, covering the period that ended on March 31, 2025 [1] - A conference call and live webcast to discuss the financial results will take place on the same day at 8:30 a.m. Eastern Time, accessible via the Azenta website [2] - A replay of the conference call will be available starting at 8:30 a.m. ET on May 8, 2025 [2] Operational Footprint - Azenta is headquartered in Burlington, Massachusetts, with operational presence in North America, Europe, and Asia [4]

Core Viewpoint - Thermo Fisher Scientific Inc. reported strong first-quarter 2025 results, with adjusted earnings per share of $5.15, surpassing analyst expectations of $5.10, and quarterly sales of $10.36 billion, slightly above the consensus estimate of $10.23 billion [1][2] Financial Performance - Adjusted operating income for Q1 2025 was $2.27 billion, a slight decrease from $2.28 billion in the same quarter last year [3] - Adjusted operating margin was 21.9%, down from 22% in Q1 2024 [3] - Organic revenue growth was recorded at 1% [1] Segment Performance - Life Sciences Solutions Segment revenue increased by 2.5% year over year to $2.34 billion [3] - Analytical Instruments Segment sales rose by 1.8% to $1.72 billion [3] - Specialty Diagnostics Segment revenues grew by 3.5% to $1.15 billion [4] - Laboratory Products and Biopharma Services segment sales decreased by 1.5% to $5.64 billion [4] Strategic Developments - The company announced an agreement to acquire Solventum's SOLV Purification & Filtration business for approximately $4.1 billion in cash, which focuses on purification and filtration technologies for biologics and medical technologies [4] Market Reaction - Following the earnings report, Thermo Fisher's stock price increased by 4.23%, reaching $453.10 [5]

Core Viewpoint - Enzo Biochem, Inc. has initiated a strategic review process to explore options for maximizing shareholder value, including potential transactions and capital returns [1][2][3] Group 1: Strategic Review Process - The Board of Directors has formed a special committee of independent directors, named the Strategic Committee, to evaluate various strategic alternatives [1][2] - The Strategic Committee has engaged BroadOak Capital Partners as financial advisor and BakerHostetler LLP as legal counsel to assist in the evaluation process [2] - There is no set timetable for the review process, and the Board has no biases towards any potential strategic alternatives at this time [3] Group 2: Company Operations and Market Position - Enzo Biochem has over 45 years of experience in the life sciences sector, primarily through its Life Sciences division, which offers a wide range of products including antibodies, genomic probes, and assays [4] - The company’s proprietary products and technologies are integral to translational research and drug development, covering areas such as cell biology and genomics [4] - Enzo Biochem has recently transferred its stock listing from NYSE to OTC, continuing to trade under the ticker symbol "OTCQX: ENZB" [5]

NEW YORK, April 22, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Maravai LifeSciences Holdings, Inc. ("Maravai LifeSciences" or the "Company") (NASDAQ: MRVI) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Maravai LifeSciences investors who were adversely affected by alleged securities fraud between August 7, 2024 and February 24, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zl ...